AU2020277525A1 - Fully human antibody targeting CD19 and application thereof - Google Patents

Fully human antibody targeting CD19 and application thereof Download PDF

Info

Publication number
AU2020277525A1
AU2020277525A1 AU2020277525A AU2020277525A AU2020277525A1 AU 2020277525 A1 AU2020277525 A1 AU 2020277525A1 AU 2020277525 A AU2020277525 A AU 2020277525A AU 2020277525 A AU2020277525 A AU 2020277525A AU 2020277525 A1 AU2020277525 A1 AU 2020277525A1
Authority
AU
Australia
Prior art keywords
amino acid
acid sequence
cells
antibody
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020277525A
Other languages
English (en)
Inventor
Zhenyu Dai
Xiangyin JIA
Taochao TAN
Qiaoe WEI
Yongkun YANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Iaso Biotechnology Co Ltd
Original Assignee
Nanjing Iaso Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Iaso Biotechnology Co Ltd filed Critical Nanjing Iaso Biotechnology Co Ltd
Publication of AU2020277525A1 publication Critical patent/AU2020277525A1/en
Assigned to Nanjing IASO Biotechnology Co., Ltd. reassignment Nanjing IASO Biotechnology Co., Ltd. Amend patent request/document other than specification (104) Assignors: NANJING IASO BIOTHERAPEUTICS CO., LTD.
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2020277525A 2019-05-20 2020-05-20 Fully human antibody targeting CD19 and application thereof Pending AU2020277525A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910419089 2019-05-20
CN201910419089.8 2019-05-20
PCT/CN2020/091235 WO2020233589A1 (zh) 2019-05-20 2020-05-20 靶向cd19的全人源抗体及其应用

Publications (1)

Publication Number Publication Date
AU2020277525A1 true AU2020277525A1 (en) 2022-01-20

Family

ID=73458076

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020277525A Pending AU2020277525A1 (en) 2019-05-20 2020-05-20 Fully human antibody targeting CD19 and application thereof

Country Status (6)

Country Link
US (2) US12516117B2 (https=)
EP (1) EP3974452A4 (https=)
JP (1) JP7566352B2 (https=)
CN (2) CN113840841B (https=)
AU (1) AU2020277525A1 (https=)
WO (1) WO2020233589A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3120563A1 (en) 2018-11-26 2020-06-04 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
AU2021298707A1 (en) * 2020-06-30 2023-02-23 Nanjing IASO Biotechnology Co., Ltd. Fully humanized bispecific chimeric antigen receptor targeting CD19 and CD22 and use thereof
WO2022257984A1 (zh) * 2021-06-08 2022-12-15 南京驯鹿医疗技术有限公司 一种增强型嵌合抗原受体(car)细胞的制备及其应用
CN114891108B (zh) * 2022-05-30 2022-11-15 上海驯鹿生物技术有限公司 一种靶向bcma的全人源抗体及其应用
CN115109140B (zh) * 2022-06-20 2026-04-28 浙江大学医学院附属第一医院 一种靶向特异肿瘤细胞的t细胞受体库构建方法
CN121127253A (zh) 2023-02-28 2025-12-12 朱诺治疗学股份有限公司 治疗系统性自身免疫性疾病的细胞疗法
EP4687962A1 (en) * 2023-03-30 2026-02-11 Cabaletta Bio, Inc. Methods and compositions for treating autoimmune diseases
WO2025147545A1 (en) 2024-01-03 2025-07-10 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids and related methods and uses
WO2026020055A2 (en) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Methods for assessing exosomes in a cell composition and related uses
WO2026050426A2 (en) 2024-08-28 2026-03-05 Juno Therapeutics, Inc. Cd19-directed chimeric antigen receptor cell therapy for treating autoimmune and neurological diseases
CN119371540B (zh) * 2024-12-10 2025-07-25 星实(上海)生物医药科技有限公司 抗cd19抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2611814A1 (en) * 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
CN101233156B (zh) 2005-06-20 2012-06-27 米德列斯公司 Cd19抗体及其用途
CL2007003622A1 (es) * 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
CN104558181A (zh) 2014-12-31 2015-04-29 四川大学 靶向b淋巴瘤细胞的人源单链抗体
CN106554414B (zh) * 2015-09-18 2019-04-23 上海科济制药有限公司 抗cd19全人抗体以及靶向cd19的免疫效应细胞
MY196631A (en) 2015-10-13 2023-04-24 Eureka Therapeutics Inc Antibody Agents Specific for Human Cd19 and uses Thereof
CN107880128B (zh) * 2017-12-21 2021-03-02 常州费洛斯药业科技有限公司 一种抗cd19的全人源抗体或抗体片段及其方法和应用
CN109293774B (zh) 2018-10-16 2021-05-28 南京医科大学 特异性结合cd19的全人源化抗体及应用
AU2021298707A1 (en) 2020-06-30 2023-02-23 Nanjing IASO Biotechnology Co., Ltd. Fully humanized bispecific chimeric antigen receptor targeting CD19 and CD22 and use thereof
WO2022257984A1 (zh) 2021-06-08 2022-12-15 南京驯鹿医疗技术有限公司 一种增强型嵌合抗原受体(car)细胞的制备及其应用

Also Published As

Publication number Publication date
US20220220200A1 (en) 2022-07-14
JP7566352B2 (ja) 2024-10-15
EP3974452A1 (en) 2022-03-30
CN113840841A (zh) 2021-12-24
US20260103517A1 (en) 2026-04-16
WO2020233589A1 (zh) 2020-11-26
CN116589579A (zh) 2023-08-15
JP2022534135A (ja) 2022-07-27
WO2020233589A9 (zh) 2021-03-25
US12516117B2 (en) 2026-01-06
EP3974452A4 (en) 2023-08-23
CN113840841B (zh) 2023-03-07
CA3141498A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
US12516117B2 (en) Fully human antibody targeting CD19 and application thereof
AU2020281380B2 (en) Antibody or chimeric antigen receptor which targets claudin 18.2
CN108137684B (zh) 抗ox40抗体及其应用
DK2215121T3 (en) ANTI-mesothelin ANTIBODIES AND USES THEREOF
CN107973854B (zh) Pdl1单克隆抗体及其应用
AU2016295601B2 (en) Tumor-specific anti-EGFR antibody and application thereof
CN112062851B (zh) 靶向bcma嵌合抗原受体的抗体及其应用
CN112745391B (zh) Pd-l1结合分子
TW202413438A (zh) 一種靶向ｐｄ－ｌ１和ｖｅｇｆ的抗體及其應用
CN119176874A (zh) 一种能够结合lilrb2的抗体或其抗原结合片段
CN113501879B (zh) 一种解除肿瘤免疫微环境中免疫抑制的双功能抗体及其应用和制备方法
CN106084046A (zh) 抗cd3单域抗体
CN106084048A (zh) 抗cd3单域抗体
CA3141498C (en) Fully human antibody targeting cd19 and application thereof
CN106117359A (zh) 抗cd3单域抗体
CN106146661A (zh) 抗cd3单域抗体
HK40072185A (en) Fully human antibody targeting cd19 and application thereof
SG11202109884WA (en) Fusion protein comprising anti-mesothelin antibody, anti-cd3 antibody or anti-egfr antibody, bispecific or trispecific antibody comprising same, and uses thereof
CN106117358A (zh) 抗cd3单域抗体
CN106084049A (zh) 抗cd3单域抗体
TW202413427A (zh) 一種靶向ｐｄ－１和ｖｅｇｆ的抗體及其應用
CN117264056A (zh) Nrp-1抗体及其用途
CN106084047A (zh) 抗cd3单域抗体
HK40052590A (en) Antibody binding human lag-3, and preparation method and use thereof
CN106117361A (zh) 抗cd3单域抗体

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: NANJING IASO BIOTECHNOLOGY CO., LTD.

Free format text: FORMER NAME(S): NANJING IASO BIOTHERAPEUTICS CO., LTD.